Daxor Corporation (DXR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Daxor Corporation (DXR) Healthcare & Pipeline Overview

Daxor Corporation, a medical device company, focuses on blood volume analysis through its BVA-100 system. This diagnostic tool offers precise blood volume quantification, setting it apart in a niche market within the broader medical instruments and supplies sector, despite facing gross margin challenges.

What Is the Investment Thesis for DXR?

Daxor Corporation presents a focused investment case centered on its BVA-100 Blood Volume Analyzer. The company's high profit margin of 6105.3% suggests significant pricing power or cost efficiencies, though this is offset by a negative gross margin of -57.5%, indicating potential issues with cost of goods sold. Growth catalysts include expanding clinical applications for BVA-100 and increasing adoption among hospitals and medical facilities. Key risks involve competition from alternative diagnostic methods and the company's small size, which could limit its ability to scale operations and compete effectively. The company's low beta of 0.14 suggests low volatility relative to the market.

Based on FMP financials and quantitative analysis

DXR Key Highlights

Market capitalization of $63.3M reflects Daxor's small size within the medical device industry.

• P/E ratio of 8.81 indicates potential undervaluation relative to earnings, but should be considered in the context of its negative gross margin.
• Profit margin of 6105.3% points to strong profitability on sales, though this may be due to one-time gains or accounting anomalies.
• Gross margin of -57.5% raises concerns about the cost-effectiveness of Daxor's operations and pricing strategy.
• Beta of 0.14 suggests the stock is less volatile than the overall market.

Who Are DXR's Competitors?

DXR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DXR's Key Strengths?

Proprietary BVA-100 technology.

• High profit margin (6105.3%).
• Established presence in blood volume analysis.
• Low beta (0.14) indicating lower volatility.

What Are DXR's Weaknesses?

Negative gross margin (-57.5%).

• Small market capitalization ($63.3M).
• Limited product portfolio focused solely on blood volume analysis.
• Reliance on a single product (BVA-100).

What Could Drive DXR Stock Higher?

Publication of clinical studies demonstrating the BVA-100's efficacy in managing specific medical conditions.

• Expansion of the BVA-100's use in new clinical settings and medical specialties.
• Development of enhanced software and data analytics tools for the BVA-100.

What Are the Key Risks for DXR?

Competition from alternative diagnostic technologies and methods.

• Changes in healthcare reimbursement policies that could impact the adoption of the BVA-100.
• The company's small size and limited resources may constrain its ability to compete effectively.
• Negative gross margins may impact long-term profitability.

What Are the Growth Opportunities for DXR?

• Expanding Clinical Applications: Daxor can drive growth by identifying and validating new clinical applications for the BVA-100. This includes exploring its use in managing heart failure, kidney disease, and sepsis, where blood volume status is a critical factor. The market for blood volume monitoring in these conditions is estimated to be substantial, with potential for increased adoption in intensive care units and cardiology practices. Success hinges on clinical trials demonstrating improved patient outcomes and cost savings.
• Geographic Expansion: Daxor has the opportunity to expand its market reach beyond its current customer base. This involves targeting international markets, particularly in Europe and Asia, where there is growing demand for advanced diagnostic technologies. Entering new markets requires regulatory approvals, establishing distribution networks, and adapting the BVA-100 to local healthcare practices. The global market for medical devices is projected to reach $600 billion by 2028, offering significant growth potential.
• Strategic Partnerships: Collaborating with hospitals, research institutions, and medical device companies can accelerate the adoption of the BVA-100. Partnering with leading hospitals can provide access to clinical expertise and patient populations for research studies. Collaborating with medical device companies can integrate blood volume analysis into existing diagnostic platforms. Strategic alliances can enhance Daxor's credibility and market presence, driving revenue growth and market share.
• Technological Innovation: Daxor can maintain its competitive edge by investing in research and development to enhance the BVA-100. This includes improving the accuracy, speed, and ease of use of the device. Developing new software and data analytics tools can provide clinicians with more actionable insights from blood volume measurements. Continuous innovation is essential to stay ahead of competitors and meet the evolving needs of the healthcare market.
• Direct-to-Patient Marketing: Daxor can explore direct-to-patient marketing strategies to raise awareness of the BVA-100 and its benefits. This involves educating patients about the importance of blood volume monitoring and encouraging them to discuss it with their doctors. Direct-to-patient marketing can increase demand for the BVA-100 and drive adoption among healthcare providers. However, this strategy requires careful consideration of ethical and regulatory issues.

What Threats Does DXR Face?

• Competition from alternative diagnostic methods.
• Evolving reimbursement policies and healthcare regulations.
• Potential for technological obsolescence.
• Dependence on a niche market.

What Are DXR's Competitive Advantages?

• Proprietary BVA-100 technology provides a unique diagnostic capability.
• Established presence in the niche market of blood volume analysis.
• Clinical data supporting the efficacy and value of the BVA-100.
• Specialized expertise in blood volume measurement technology.

What Does DXR Do?

Daxor Corporation, originally incorporated as Idant Corporation in 1971 and renamed in 1973, is a medical device company headquartered in Oak Ridge, Tennessee. The company specializes in blood volume measurement technology, primarily through its development and marketing of the BVA-100 Blood Volume Analyzer. This diagnostic tool provides clinicians with precise quantification of a patient's blood volume status and composition, compared against patient-specific norms. The BVA-100 is utilized across a spectrum of medical and surgical conditions, offering objective data to guide treatment decisions. Daxor's focus remains on refining and expanding the applications of its blood volume analysis technology within the medical field. The company's evolution has been marked by a consistent commitment to advancing diagnostic capabilities related to blood volume assessment, positioning it as a specialized player in the medical device market. With a relatively small team of 37 employees, Daxor maintains a concentrated approach to its core technology and market niche.

What Products and Services Does DXR Offer?

• Develops and markets the BVA-100 Blood Volume Analyzer.
• Provides diagnostic blood tests for quantifying blood volume status.
• Offers technology used in a range of medical and surgical conditions.
• Quantifies blood volume composition compared to patient-specific norms.
• Focuses on blood volume measurement technology.
• Aids clinicians in making informed treatment decisions based on objective blood volume data.

How Does DXR Make Money?

• Sells the BVA-100 Blood Volume Analyzer to hospitals and medical facilities.
• Generates revenue from the sale of BVA-100 testing kits and consumables.
• Provides service and maintenance contracts for the BVA-100 system.

What Industry Does DXR Operate In?

Daxor Corporation operates within the medical instruments and supplies industry, a segment characterized by technological innovation and stringent regulatory oversight. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in diagnostic technologies. Daxor's BVA-100 competes with other diagnostic methods for assessing patient health, including traditional blood tests and imaging techniques. The company's success depends on demonstrating the clinical value and cost-effectiveness of its blood volume analysis technology compared to these alternatives. The industry is also subject to evolving reimbursement policies and healthcare regulations, which can impact the adoption of new medical devices.

Who Are DXR's Key Customers?

• Hospitals and medical centers.
• Cardiology practices.
• Intensive care units.
• Nephrology clinics.

Over the past six months, Daxor Corporation insiders filed 12 SEC Form 4 transactions — 0 sales and 12 purchases. On net that is roughly 87K shares acquired (about $120K) — insiders putting money in tends to read as conviction.

Daxor Corporation has missed Wall Street's EPS estimate in 3 of its last 5 reported quarters — a mixed record worth weighing. Reported results have landed about 617.5% below estimates on average.

Daxor Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.

Return on equity for Daxor Corporation stands at 22.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 19.9%, showing how much profit it generates from its asset base. DXR trades at a trailing price-to-earnings ratio of 8.81, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 0.3%, a gauge of the cash the business throws off relative to its market value. Its earnings yield is 17.6%, the inverse of the P/E and a quick read on earnings relative to price.

Daxor Corporation (DXR) Valuation Context

Valued at $63.3M, DXR is classified as a micro-cap stock. Analyst price targets span from $23.00 to $23.00, with a consensus of $23.00. At the current price of $10.84, that implies approximately 112% upside potential. Relative to its peer group, DXR's quantitative score of 48/100 is above the peer average of 33/100.

DXR Revenue & Earnings Trend

In Q2 FY2026, DXR generated $23K in top-line revenue, marking a sequential decrease of 82.5%. The company recorded a net loss of $3.3M, with diluted EPS of $-0.66. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, DXR averaged $0.40 in diluted EPS.

Company Profile

Daxor Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Oak Ridge, US. The company is led by CEO Michael Richard Feldschuh. DXR has traded publicly since 1983.

DXR Financials

DXR Latest News

DXR Analyst Consensus

DXR MoonshotScore

DXR Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources